LEARN ABOUT SUPRACHOROIDAL ADMINISTRATION

FIRST & ONLY FDA APPROVED PRODUCT FOR SUPRACHOROIDAL ADMINISTRATION

XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use

  • FIRST approved therapeutic delivered into the suprachoroidal space
  • FIRST commercial product developed by Clearside
  • FIRST therapy for macular edema associated with uveitis
Learn About XIPERE®

UNPRECEDENTED ACCESS TO THE BACK OF THE EYE

We are redefining the treatment of retinal diseases. The back of the eye is the location of many irreversible and debilitating ocular conditions, and our proprietary technology precisely administers drug at the site of disease. Our innovative delivery approach revealed that when fluid is injected between the choroid and sclera, the elasticity of the suprachoroidal space (SCS®) allows the drug product to spread spherically toward the posterior regions of the eye where it is absorbed into adjacent, diseased tissue.

UNDERSTAND THE SUPRACHOROIDAL SPACE

MAKING A DIFFERENCE FOR PATIENTS

We are dedicated to developing and delivering treatments that preserve and improve vision for people with serious back of the eye diseases

VIEW OUR CLINICAL PROGRAMS

MAKING A DIFFERENCE FOR PATIENTS

We are dedicated to developing and delivering treatments that preserve and improve vision for people with serious back of the eye diseases

LEARN ABOUT OUR CLINICAL TRIALS